JLR: A close-up of the lipids in Niemann–Pick disease
Researchers at the University of Illinois at Chicago have used mass spectrometry imaging to map lipid accumulation in Niemann–Pick disease with unprecedented detail. Their results were published in a recent issue of the Journal of Lipid Research.
There are three major forms of Niemann–Pick disease. All are genetic and rare. Type C, or NPC, results in accumulation of cholesterol and complex lipids known as gangliosides in the endosomes and lysosomes of cells. This accumulation leads to neurodegeneration, killing patients when they are young. Many die before they’re 10. It’s rare for one to live to 40.
This image of a cerebellum from a mouse with Niemann–Pick C was generated using fluorescence immunolabeling, which is an effective technique for determining protein distribution but cannot capture the location of gangliosides and other lipids that accumulate and cause the disease.Williams/NICHD
Based on the way movement and cognition problems emerge in NPC, it seems that different brain regions degenerate at varying stages of the disease. To understand this staging better, it would be useful to visualize lipid accumulation in specific brain regions. This isn’t easy to do with traditional methods, because antibodies against gangliosides are not very specific, so most studies of lipid accumulation in Niemann–Pick disease use homogenized tissue samples from mice with the disease and measure bulk lipids by mass spectrometry.
To achieve greater spatial accuracy, researchers in Stephanie Cologna’s lab used mass spectrometry imaging to look closely at lipids in specific regions of the cerebellum in mice with early-stage NPC. Mass spectrometry imaging, which does not require antibodies or chemical labeling, works by representing small areas of a tissue sample as pixels. The researcher coats a tissue sample in a matrix that helps it to ionize and then collects mass spectra from many tiny areas within that sample.
Each spectrum from one pixel includes information about the abundance of many lipid species. The team used the information about different molecules to make images representing the distribution of lipids across the cerebellum.
Mindful of variations in the intensity of matrix-assisted laser desorption/ionization spectra that can arise from uneven application of the matrix or variability among samples, the team, led by graduate student Fernando Tobias, also devised an algorithm to evaluate the most abundant signals. The algorithm let them filter out noise and compare measurements of wild-type and NPC brain samples more reliably with many replicates.
Once they compared lipid distributions across the cerebellum, the team made the interesting observation that, while two types of ganglioside (GM2 and GM3) are drastically higher in the NPC mouse’s cerebellum, GM1 seems to go up throughout the brain. Also, GM2 elevation is very tightly localized in a part of the cerebellum called lobule X, but it’s not yet clear what that might mean.
The researchers intend to continue using mass spectrometry imaging to get a more granular picture of the disease course.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.